BX Pulsar 1002 for Obsessive-Compulsive Disorder
Study Summary
This trial is to study the safety and feasibility of using a technology called Low Intensity Focused Ultrasound (LIFU) to treat patients with obsessive-compulsive disorder (OCD). The device is used to send high frequency sound waves to a particular region of the brain called the Ventral Striatum (VS). LIFU is a non-invasive form of stimulation, which can be used to stimulate deep regions of the brain. The trial will last two weeks with three weekly treatment sessions.
- Obsessive-Compulsive Disorder
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Does this clinical trial currently have open spots for volunteers?
"Affirmative. Evident from the information on clinicaltrials.gov, this medical research is now recruiting individuals for participation. The trial was first announced on August 1st 2022 and its latest update was released in September 12th 2022. This project requires 20 patients to take part at 2 distinct sites."
Does the criteria for eligibility in this trial encompass individuals of a younger age?
"As per the stipulations of this medical study, participants must be between 21 and 55 years old."
Could I potentially qualify to partake in this medical experiment?
"Those who wish to join this clinical trial must possess a diagnosis of obsessive-compulsive disorder and fall within the 21–55 age bracket. At present, the study is looking for around 20 participants."
What is the scope of participation for this research endeavor?
"Affirmative. The trial's posting on clinicaltrials.gov confirms that it is still recruiting patients, which began on August 1st 2022 and was last revised in September of the same year. A total of 20 individuals are required to take part across two sites."